Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Onabotulinum toxin A - AbbVie

Alternative Names: BoNTA; Botox; Botulinum toxin A injectable-AbbVie; GSK 1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie; Allergan; GlaxoSmithKline; GSK; Johns Hopkins University; Queens University; Temple University; University of Illinois at Chicago; Wake Forest University School of Medicine
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Torticollis; Strabismus; Muscle spasticity; Blepharospasm
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dysphonia; Facial wrinkles; Glabellar lines; Hyperhidrosis; Hypertrophy; Migraine; Muscle spasticity; Neurogenic bladder; Overactive bladder; Strabismus; Torticollis
  • Registered Equinus foot deformity
  • Phase III Muscle pain; Raynaud's disease
  • Phase II Carpal tunnel syndrome; Essential tremor; Gastrointestinal disorders; Herpes labialis; Interstitial cystitis; Major depressive disorder; Musculoskeletal pain; Neuropathic pain; Pain; Premature ejaculation
  • Phase I/II Pruritus
  • No development reported Benign prostatic hyperplasia; Constipation; Prostatitis
  • Discontinued Diabetic gastroparesis; Gilles de la Tourette's syndrome

Most Recent Events

  • 03 Feb 2025 AbbVie completes a phase-II trial in Essential tremor in Canada (IM) (NCT05216250)
  • 27 Jan 2025 AbbVie plans a phase-III trial for Facial wrinkles in Japan (IM), (NCT06794866)
  • 06 Dec 2024 AbbVie completes a phase-II clinical trials in Interstitial cystitis in USA and Canada (IM) (NCT05141006)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now